Gogoro Inc vs Royalty Pharma plc Class A Ordinary Shares — how do they compare? Gogoro Inc trades at $3.02 (market cap $56.21M), while Royalty Pharma plc Class A Ordinary Shares trades at $56.88 (market cap $25.27B). The key difference: Royalty Pharma plc Class A Ordinary Shares is far larger — about 449.6× Gogoro Inc's market cap, and Royalty Pharma plc Class A Ordinary Shares pays a 1.66% dividend while Gogoro Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gogoro Inc for 14 Days and Royalty Pharma plc Class A Ordinary Shares for 1 Days on average.
| GGR | RPRX | |
|---|---|---|
Market Cap | $56.21M | $25.27B |
Volume | 14,026 | 3,671,183 |
Sector | Consumer Cyclical | Health |
52-Week High | $5.15 | $63.96 |
52-Week Low | $2.20 | $35.44 |
Typical Hold Time | 14 Days | 1 Days |
Enterprise Value | $342.65M | $32.50B |
Dividend Yield | — | 1.66% |
Signals from Pluang's Aura AI — not financial advice
GGR trades at $2.99, down 6.27% today, with a bullish technical signal from moving averages but negative profitability metrics including a -16.68% net income margin. Recent developments include new board appointments and a $61.8 million equity investment announced in October 2026. The company shows revenue growth from $281 million in 2025 to $286 million projected for 2026, though net losses persist.
The outlook remains cautious with 100% hold ratings from analysts. Investment appeal lies in the low P/S of 0.18 and EV/EBITDA of 6.38, but risks include sustained negative cash flow and high debt-to-asset ratio of 60%. Positive technical momentum contrasts with fundamental challenges in achieving profitability.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Gogoro is a global technology leader in battery-swapping ecosystems for electric two-wheelers. It provides smart, sustainable urban mobility solutions and manages an extensive network of battery stations.
Read more on GGR →Royalty Pharma acquires interests in royalties from biopharmaceutical products. Its model gives it exposure to medicines developed and sold by other life sciences companies.
Read more on RPRX →